【Health and Welfare News】Gilead Sciences Korea announced on the 10th that it will launch ‘HIVISION,’ a website containing information on HIV disease.
Gilead explained the reason for opening the Hi-Vision website, saying, “To correct misinformation and create correct awareness about HIV.”
To this end, Hi-Vision consists of ▲disease information ▲diagnosis ▲treatment ▲campaign to improve awareness of HIV ▲prevention ▲locating public health centers for testing ▲frequently asked questions (FAQ), etc.
“HIV has become a chronic disease that can be managed like diabetes, but patients are missing out on appropriate diagnosis and treatment due to incorrect information and negative perceptions,” said Seonhee Kwon, executive director of Gilead Sciences Korea’s HIV division and digital marketing. “Visit the Hi-Vision website.” “We hope that accurate information about HIV will be delivered through this and ultimately contribute to improving the health of patients,” he emphasized.
Gilead has a diverse HIV portfolio ranging from prevention to treatment. Starting with Truvada, a preventive therapy, the company launched Genvoya, Descovy, and Biktarvy, a single-tablet triple-drug treatment for HIV.
Biktarvy can be easily taken once a day, regardless of meal, and has a low possibility of drug interaction and a high barrier to resistance. Biktarvy recently announced the results of a 5-year long-term data analysis, reaffirming its long-term viral suppression effect, excellent tolerability, and safety.
Please note that posts that are not related to the content of the article or that defame others, such as using profanity, may be deleted without notice by the administrator.
2023-10-10 01:17:00
#Gilead #launches #Hivision #website #HIV #disease #Health #Welfare #Newspaper
